• News
  • BioTech

Ginger L. Graham

Related Special Reports


Amylin Pharmaceuticals Inc.

Amylin Pharmaceuticals (Nasdaq: AMLN) is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases.

Ginger Graham

Graham is the former group chairman, office of the president for Guidant Corp. (NYSE: GDT), located in Indianapolis, Ind. From 1993 to 2000, Graham was president and CEO of Advanced Cardiovascular Systems and, with the creation of Guidant in 1994, became president of the vascular intervention business group.

Graham started her career with Eli Lilly and Co. (NYSE: LLY) and served in a number of management positions. Her diverse career path gave her the opportunity to work in a variety of industries, including agriculture, cosmetics, pharmaceuticals, investment banking and medical technology.

A native of Springdale, Ark., Graham received a Bachelor's of Science degree in agricultural economics from the University of Arkansas. She also holds a Master's of Business Administration degree from Harvard University.

Graham serves on the board of directors for Amylin Pharmaceuticals, PhRMA (Pharmaceutical Research and Manufacturers of America), and the California Council on Science and Technology. She also serves on the advisory board for the Kellogg Center for Executive Women, the Harvard Business School Health Industry Alumni Advisory Board, and the University of California, San Diego Health Sciences Advisory Board.

Graham frequently speaks at business schools and has written for Harvard Business Review.

User Response
0 UserComments